Roche’s Gene Therapy for Duchenne Muscular Dystrophy Faces EU Approval Setback
Roche Holding AG’s gene therapy, Elevidys, has been rejected by the European Medicines Agency, dealing a setback to the company’s efforts to treat Duchenne muscular dystrophy.
2 minutes to read









